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Genetic polymorphisms of the renin-angiotensin-aldosterone Nephropathies of any etiology tend to progress to end-
system in end-stage renal disease. stage renal disease (ESRD) more or less rapidly over
Background. Hypertension contributes to the progression time [1]. The resulting costs of treatment for ESRD areto renal failure. A genetic susceptibility to hypertension may pre-
enormous. Hypertension is the major contributor in thedispose to the development of end-stage renal disease (ESRD)
progression of renal failure in patients with renal diseaseand promote a more rapid progression to ESRD in patients
with renal diseases. Genes encoding for angiotensinogen (AGT), both with and without proteinuria [2]. Moreover, hyper-
angiotensin-converting enzyme (ACE), and aldosterone syn- tension per se is a risk factor for the development of
thase (CYP11B2) are candidates for abnormal blood pressure ESRD [3, 4]. On the other hand, the prevalence of hyper-regulation.
tension increases with decreasing renal function [5]. ThisMethods. Genotyping was performed in 327 control subjects
results from both a decreased sodium excretion and anand 260 ESRD patients for the M235T-AGT, the insertion/
deletion (I/D)-ACE, and the 344T/C-CYP11B2 gene poly- activation of the renin-angiotensin-aldosterone system
morphisms using polymerase chain reaction, gel analysis, and (RAS). Therefore, it is possible that a genetic predisposi-
appropriate restriction digest when required.
tion to salt-dependent hypertension or overactivation ofResults. Genotype frequencies did not differ significantly
the RAS may (1) predispose to the development of renalbetween ESRD patients and controls. When ESRD diabetic
subjects were compared with diabetic patients without nephropa- failure and (2) promote a more rapid loss of glomerular
thy, the prevalence of the AGT-MM genotype was lower (28.1 filtration rate in patients suffering from renal diseases.
vs. 52.8%, P  0.01), while the AGT-TT genotype was higher Thus, genes that regulate renal sodium reabsorption or
(15.6 vs. 2.7%, P  0.05). The AGT-TT genotype was associ-
genes of the RAS may be extremely important in patientsated with a faster progression to ESRD in patients with glomer-
suffering from ESRD. Among the candidate genes of theulonephritis (P 0.05). In the total ESRD population, progres-
sion of renal disease was faster with the ACE-DD than with RAS, the angiotensinogen gene (AGT), the angiotensin-
the DI and II alleles (P  0.05). This association was particu- converting enzyme gene (ACE) and the aldosterone syn-
larly strong when the interaction with the AGT genotype was thase gene (CYP11B2) are of particular interest.analyzed, with a rapid progression in ACE-DD as compared
Two molecular variants of the AGT, the T174M andwith ACE-DI and II in patients with the AGT-MM genotype
M235T, were analyzed in an associated study in selected(P  0.01).
Conclusions. Susceptibility for ESRD and faster progression hypertensive subjects in two distinct American and
to ESRD are linked with the AGT genotype in diabetic pa- French populations [6]. Both T174M and M235T variants
tients. Faster progression to ESRD is associated with the ACE were significantly more frequent in all hypertensive casesgenotype when the total population with ESRD and with the
than in controls, with a further increase in frequencyAGT genotype when patients with glomerulonephritis are con-
among the more severely affected cases. Moreover, thesidered. Thus, genes of the renin-angiotensin-aldosterone sys-
tem are candidate genes for further understanding of the inter- M235T variant was associated with a high plasma level
individual differences in the development and course of ESRD. of AGT in hypertensive subjects.
An insertion/deletion (I/D) polymorphism in intron
16 of the ACE has been described by Rigat et al [7]. In
subjects with the deletion polymorphism (DD), plasma
ACE activity was fourfold higher than in subjects homo-
zygous for the insertion allele, suggesting that the DDKey words: angiotensinogen, hypertension, aldosterone synthase, renal
failure, blood pressure, progressive renal disease. polymorphism could be a marker for a high serum ACE
level intermediate phenotype [7]. The DD polymorphismReceived for publication August 18, 2000
has been associated with an increased risk of myocardialand in revised form January 30, 2001
Accepted for publication February 7, 2001 infarction [8], although not with the development of cor-
onary stenosis [9] and with idiopathic dilated cardiomy- 2001 by the International Society of Nephrology
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Table 1. Baseline demographic characteristics of the 587 subjects studied, subdivided by population groups
Control subjects (N  327) ESRD patients (N  260)
Healthy Hypertension Diabetes Dialysis Transplantation
N 162 128 37 102 158
Sex Male/Female 95/67 70/58 21/16 59/44 89/69
Age years 4916 5917b 5221 6413b 4812c
BMI kg/m2 23.54.0 28.16.0b 25.94.6a 25.04.3a 24.94.6a
Blood pressure mm Hg
Systolic 12915 15421b 14423b 15026b 13714bc
Diastolic 789 9014b 829a 8115 868bc
Abbreviations are: ESRD, end-stage renal disease; BMI, body mass index.
Data are mean  SD.
a P  0.01, b P  0.0001 vs. healthy controls
c P  0.0001 vs. dialysis patients
opathy [10]. In a small group of patients with essential and second whether polymorphisms of these genes are
hypertension, the percentage of DD polymorphism was associated with a more rapid progression to ESRD.
higher in hypertensive subjects whereas the II polymor-
phism was more frequent in normotensive controls [11].
METHODSHomozygosity for D allele was associated with an in-
Subjectscreased risk of developing ESRD at early age in polycys-
tic kidney disease patients [12, 13] and with a shorter Study subjects were 260 white patients with ESRD
time of graft survival in kidney transplant recipients [14]. (either dialysis or transplanted) from our Division of
However, in IgA glomerulonephritis (IgA GN), geno- Nephrology and Hypertension (University Hospital of
type distributions and allele frequencies were not sig- Berne, Berne, Switzerland) and 327 white control sub-
nificantly different between controls and patients with jects without renal diseases (Table 1). The geographic
nephritis and stable renal function [15]. origin of 519 out of 587 subjects was the Swiss German
Expression of the CYP11B2 gene is regulated by an- area, while the remaining 68 consisted of subjects from
giotensin II through cAMP-dependent modulation of the the North Mediterranean area (N 48), Eastern Europe
gene promoter region containing a variety of control (N 14), and Asia or Africa (N 6). Basic demographic
factors, one of which is the steroidogenic factor-1 (SF1) data, including current blood pressure, information on
[16, 17]. Evidence for a genetic variant in the SF1 site associated diseases and current medication, including the
of the CYP11B2 was found in two independent hyperten-
type and number of antihypertensive drugs, were ob-
sive populations, suggesting that mutations of this en-
tained for all subjects. In the control group, serum creati-
zyme may be relevant in hypertension [18, 19]. This vari-
nine was 104 mol/L, proteinuria was 30 mg/L, andant consists in a single nucleotide polymorphism at
urinary sediment was normal in all subjects. All diabeticposition 344 of the CYP11B2 promoter (344C/T).
patients in the control and ESRD groups had insulin-Differences in the structure of this site alter the sensitiv-
dependent diabetes mellitus. For ESRD patients, the dateity to angiotensin II [19]. Besides hypertension, this poly-
of diagnosis of the renal disease, renal histology, time ofmorphism in the SF1 has been associated with increased
onset of ESRD, type of renal replacement treatment,left ventricular size and impaired diastolic function [20].
age at transplantation, blood pressure in the pre-ESRDThis finding was confirmed in another study in which
period, and other information were also available. Sub-the344C variant was also associated with a higher ratio
jects admitted to our service with serum creatinine150of aldosterone-to-plasma renin activity as well as with
mol/L (1.7 mg/dL) and whose renal history could nothypertension [21].
be retrieved were excluded. The time from diagnosis ofTo date, no study has analyzed the prevalence and
the renal disease to the onset of ESRD was used as adistribution, alone or combined, of the M235T-AGT,
measure for progression. A subgroup analysis by diagnosisI/D-ACE, or 344C/T-CYP11B2 polymorphisms and
of renal disease was performed for the following etiolo-their relationship with the time of onset of ESRD, time
gies: glomerulonephritis (N  76), interstitial nephritisfrom diagnosis to ESRD, and age of patients at the time
(N  40), diabetes mellitus (N  32), autosomal-domi-of ESRD in a population of patients with chronic renal
nant polycystic kidney disease (N  30), pyelonephritis/failure of comparable ethnical background but with renal
vesicoureteral (N  25), nephroangiosclerosis (N  14),diseases of different etiology. Therefore, this study
and others (N  40). In patients with autosomal-domi-aimed at establishing first whether polymorphic variants
in these genes are more prevalent in ESRD patients, nant polycystic kidney disease, progression was defined
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Table 2. Oligonucleotides for amplification and screening
Gene Sequence Cycling conditions
AGT
Sense 5-CCGTTTGTGCAGGGCCTGGCTCTCT-3 30  (94	C 30 sec, 68	C 60 sec, 72	C 30 sec)
Antisense 5-CAGGGTGCTGTCCACACTGGACCCC-3
ACE-1
Sense 5-CTGGAGACCACTCCCATCCTTTCT-3 28  (94	C 60 sec, 62	C 45 sec, 72	C 60 sec)
Antisense 5-GATGTGGCCATCACATTCGTCAGAT-3
ACE-2
Sense 5-TGGGACCACAGCGCCCGCCACTAC-3 28  (94	C 30 sec, 67	C 45 sec, 72	C 120 sec)
Antisense 5-TCGCCAGCCCTCCCATGCCCATAA-3
CYP11B2
Sense 5-CAGGGGGTACGTGGACATTT-3 35  (94	C 30 sec, 52	C 30 sec, 72	C 30 sec)
Antisense 5-CAGGGCTGAGAGGAGTAAAA-3
Cycling conditions are number of cycles  (temperature and time of denaturation, annealing, and elongation).
as the time when serum creatinine increased120mol/L Polymorphism analysis of the CYP11B2 gene was per-
formed by restriction typing of PCR products from theuntil the time of onset of ESRD.
Genetic analysis for the M235T-AGT, D/I-ACE, and promoter region of the CYP11B2 gene using the primers
and the cycling conditions reported in Table 2.344C/T-CYP11B2 genotypes was performed in all 587
subjects, and the prevalence of identified polymorphisms
Gel analysis and genotypingwas analyzed in patients with ESRD as compared with
control subjects for susceptibility to renal diseases and Polymerase chain reaction products were analyzed on
12% acrylamide gels containing 7.25% glycerol using awithin the ESRD population for the progression of renal
function loss. two-buffer system, either native or after appropriate re-
striction digest. Four microliters of the PCR sample were
DNA preparation and polymerase chain loaded, and DNA was visualized by silver staining [22].
reaction analysis For the analysis of the AGT M235T polymorphism,
PCR products were digested with AspI for two hours atGenomic DNA was isolated from peripheral blood
using the Nucleon BACC3 DNA extraction kit (Amer- 37	C, obtaining for the M235 variant a 165 bp fragment
and a 144 bp fragment for the T235 variant.sham Intl., Buckinghamshire, UK). Detection of poly-
morphisms was performed by polymerase chain reaction For the analysis of the ACE D/I polymorphism, the
PCR product shows a 190 bp fragment in the absence(PCR) analysis using the primers reported in Table 2. All
reactions were performed with 10 pmol of each primer in of the insertion (D allele) and a 490 bp fragment in the
presence of the insertion (I allele). Products in whicha final volume of 50 L, containing 1.5 mmol/L MgCl2
(except for ACE1 3 mmol/L MgCl2), 10 mmol/L Tris HCl only the D fragment was present were further analyzed
as described previously in this article. Where mistyping(pH 8.3), 50 mmol/L KCl, 200 mol/L dNTPs, and 1 U
of AmpliTaq Gold polymerase (PE Biosystems, Foster was present, a 335 bp product was identified (ID geno-
type), while no band was detected when the DD typingCity, CA, USA).
Polymorphism detection for the AGT gene was per- was correct.
For the analysis of the CYP11B2-344C/T polymor-formed by restriction typing of PCR products using the
primers and the cycling conditions reported in Table 2. phism, PCR products were digested with HaeIII for two
hours at 37	C. The 344T allele lacks the HaeIII siteTo introduce the second part of the half-site produced
by the T→C transition at nucleotide 704 in exon 2 of (GGCC) present in the 344C allele. In the presence
of the 344C allele, the PCR product (152 bp) was cutthe AGT gene, an antisense PCR primer with two mis-
matches was used (Table 2, primer 2, underlined). into two fragments of 97 bp and 56 bp.
The amplification of intron 16 in the ACE gene con-
Statisticstaining the insertion was performed using the primers
and cycling conditions shown in the Table 2. Because Values are expressed as mean  SD or percentage.
Statistical differences between means were assessed bythe D allele in heterozygous samples is preferentially
amplified, each sample found to have the DD genotype t test or analysis of variance (ANOVA) for analysis of
continuous variables and by nonparametric analysis us-was subjected to a second independent PCR amplifica-
tion with primers that recognize an insertion-specific se- ing the Wilcoxon or Kruskal–Wallis test for variables
that were not normally distributed. For categorical vari-quence (primers N  5 to 6). The reaction yields a PCR
product only in the presence of an I allele and no product ables, the 2  2 contingency table 
2 test was used. The
expected “disease” frequency for the target populationin samples homozygous for DD.
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Table 3. Comparison of allelic frequencies in percentage among
controls and ESRD patients
AGT ACE CYP11B2
T D T
Cases N %
Controls 654 39.6 48.3 53.2
Normal 324 39.8 49.1 53.4
Hypertension 256 43.0 49.2 51.6
DM 74 27.0a 41.9 58.1
ESRD 520 42.5 45.6 51.2
Dialysis 204 42.7 42.2 51.0
Transplanted 316 42.4 47.8 51.3
a P 0.01 vs. normal controls and patients with hypertension (ANOVA, F ratio
4.902).
was calculated according to the Hardy–Weinberg equa-
tion [23]. All statistical analyses were performed using
Fig. 1. AGT genotypes in patients with diabetes mellitus without ne-
the Systat 8.0 (SPSS Inc., Chicago, IL, USA) statistical phropathy (, N  37) or with diabetic ESRD (, N  32). Cochran’s
linear trend P  0.01.software package. Polymorphic biallelic pairs are shown
for the combinations supposed to protect against or pre-
dispose to high blood pressure only.
leles, the genotype and its interactions with the ACE
RESULTS and CYP11B2 genotypes were analyzed in all 69 patients
with diabetes mellitus. Observed frequencies for theBaseline demographic data of the subjects investigated
AGT genotype in control patients with diabetes mellitusin the present study are outlined in Table 1 and are
were in Hardy–Weinberg disequilibrium when comparedsubdivided by the different population subgroups. Allele
with the expected frequencies calculated from allelic dis-frequencies in controls and ESRD patients stratified by
tribution in the entire diabetic population. The preva-subgroups for the AGT, ACE, and CYP11B2 genes are
lence of the AGT-MM genotype was significantly higherreported in Table 3. In the ESRD group at the time
in diabetic controls and the AGT-TT genotype substan-of renal diagnosis, patients were comparable for renal
tially higher in diabetic ESRD patients (Pearson 
2 P function and incidence of proteinuria or diabetes among
0.05, Cochran’s linear trend, P 0.01; Fig. 1). A compari-the different genotype subgroups. When renal function
son of biallelic frequencies alone or combined in controlsat the time of diagnosis was analyzed for the genotype
and ESRD patients is shown in Table 4. Biallelic pairssubgroups, serum creatinine was 139  6 (MM), 136 
are shown for the combinations that are supposed to4 (MT), 142 5 (TT) mol/L when patients were subdi-
protect against or predispose to high blood pressure asvided for their AGT polymorphism; 136  6 (II), 139 
described previously in this article. Since the combined4 (DI), and 135  7 (DD) mol/L when analyzed for
prevalence of homozygosity for these polymorphisms wasthe ACE polymorphism; and 141  7 (CC), 136  4
low, data for the frequencies in the subgroups (healthy(CT), and 138  6 (TT) mol/L when the CYP11B2
subjects, patients with hypertension, diabetes mellitus,polymorphism was considered. The incidence of diabetes
on dialysis or with a transplant) are not shown.mellitus ranged between 10 and 17%, and the prevalence
Genetic polymorphisms were analyzed for their rela-of proteinuria 1.5 g/day at diagnosis ranged between
tionship to the rate of progression of renal disease and33 and 44% among the different genotype subgroups
to blood pressure or the presence or absence of hyperten-without significant within-group differences. The geno-
sion. Progression of renal disease in the ESRD popula-type of the three genes studied was analyzed for an
tion as a whole was influenced by the ACE polymor-association with the susceptibility to renal diseases. The
phism. The time from diagnosis to the onset of ESRDexpected frequencies of the AGT, ACE, and CYP11B2
was shorter in the presence of the ACE-DD (N  42)genotypes, under the assumption of the Hardy–Weinberg
than with DI (N  155) or II (N  63) alleles (Kruskal–equilibrium, did not differ from observed frequencies
Wallis test  8.11, P  0.05; Fig. 2A). Differences be-in ESRD patients and control subjects. The AGT-235T
tween women and men in relationship to the ACE genevariant was lower in patients with diabetes mellitus than
polymorphism have been suggested [24]. Progression toin healthy controls or controls with hypertension (F ratio
ESRD was more rapid in men than in women (9.5  0.74.902, P  0.01). Since diabetic patients without ne-
phropathy had a lower prevalence of the AGT-TT al- vs. 11.9 1.0 years, P 0.042). The presence of the II or
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Table 4. Comparison of biallelic frequencies alone and combined
among controls and end-stage renal disease (ESRD) patients
Controls ESRD
%
AGT
MM 36.8 30.8
TT 16.4 15.8
ACE
II 21.1 24.3
DD 19.2 15.8
CYP11B2
CC 23.8 22.8
TT 31.6 25.5
AGT/ACE
MM/II 7.7 8.1
TT/DD 3.4 1.5
AGT/CYP11B2
MM/CC 8.6 6.5
TT/TT 6.1 3.1
ACE/CYP11B2
II/CC 5.2 7.3 Fig. 3. AGT genotype and rate of progression of renal disease in years
DD/TT 4.9 4.6 from the time of diagnosis to the onset of ESRD in 76 patients with
glomerulonephritis (F ratio  3.821, P  0.05).Biallelic pairs are shown for the combinations that are supposed to protect
against or predispose to high blood pressure. For instance, since the AGT-M235T
allele has been associated with high angiotensin levels and the ACE-DD variant
was found to have higher plasma ACE activity, a combination of both (AGT-
TT  ACE-DD) would more likely be associated with hypertension and ESRD
among all ESRD patients. When progression in ESRDthan the mirror combination (AGT-MM  ACE-II).
patients was tested for an association with the underlying
renal disease, the AGT-TT genotype was associated with
a slightly higher progression to ESRD in patients with
glomerulonephritis (F ratio  3.821, P  0.05; Fig. 3).
In the non-ESRD population, no relationship between
either systolic or diastolic blood pressure and the AGT,
ACE, or CYP11B2 genotypes was found. The prevalence
of AGT-TT/ACE-DD (5.5 vs. 2.4%, P  0.01) was
higher, and that of the AGT-MM/ACE-II was lower (4.7
vs. 8.6%, P  0.05) in patients with hypertension than
in healthy controls. In the control group, homozygosity
for the AGT-235T genotype was associated with higher
diastolic but not systolic blood pressure (144/87 
Fig. 2. (A) ACE genotype and rate of progression of renal disease in
25/16 mm Hg, N  52) as compared with the MMyears from the time of diagnosis to the onset of end-stage renal disease
(ESRD) in the entire ESRD population (DD vs. DI II Kruskal–Wallis (139/81  21/11 mm Hg, N  116) or the MT (141/84 
test  8.11, P  0.05). (B) Interaction between the AGT and the ACE 21/12 mm Hg, N  148) genotypes. No association was
gene polymorphisms on the rate of loss of renal function for 78 ESRD
found with either the ACE or CYP11B2 polymorphismpatients homozygous for the AGT MM gene (F ratio  4.856, P  0.01).
and diastolic or systolic blood pressure. A general linear
model analysis of the effect of the three gene polymor-
phisms on systolic or diastolic blood pressure did not
DI genotype accounted for this difference with a shorter reveal any context dependency among these gene poly-
time from diagnosis to ESRD in men than women (9.7 morphisms and blood pressure.
vs. 12.5 1.1 years, P 0.036), while the effect of the DD
genotype on the progression to ESRD was comparable
DISCUSSIONbetween genders (7.6  1.4 vs. 9.1  2.5 years). The
association of progression of renal failure with the ACE We have analyzed three gene polymorphisms of the
RAS for association with ESRD. The RAS is a logicalI/D polymorphism was particularly strong when the in-
teraction with the AGT genotype was analyzed, with a target because (1) an increased activity of the RAS causes
angiotensin II-mediated vasoconstriction and aldosteronerapid progression in ACE-DD (N 12) as compared with
ACE-DI (N  46) and II (N  20) in patients with the release with subsequent plasma volume expansion, re-
sulting in hypertension; and (2) angiotensin II plays anAGT-MM genotype (F ratio  4.856, P  0.01; Fig. 2B).
No significant association was found between the AGT important role in the progression of renal diseases. In
fact, angiotensin II effects on hemodynamics, such as in-or CYP11B2 genotype and progression of renal failure
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creased systemic and glomerular blood pressure, and on tension [36]. In our population, however, the effect of
ACE gene I/D polymorphism on the rate of progressiontissue growth, including promotion of mesangial hyper-
trophy and fibrosis, are both thought to be responsible to renal failure, analyzed by the presence or absence of
proteinuria or hypertension, did not show any significantfor progressive loss of renal function [25, 26]. Even more
relevant in this regard could be the recent description differences. This might be due to the small number of
patients in each subgroup. A significant correlation be-of the intrarenal RAS [27, 28], which is thought to con-
tribute to long-term blood pressure regulation by inte- tween the rate of progression of renal failure and the
AGT genotype was found for patients with glomerulo-grating distant tubular sodium-reabsorbing functions.
To minimize the probability of equivocal results, a nephritis of any etiology (Fig. 3), an observation in accor-
dance with the report of Pei et al of a more rapid progres-sufficiently large sample size (260 ESRD patients and
327 controls) with a high ethnic homogeneity and an sion with the AGT-TT than with AGT-TM or AGT-MM
alleles in IgA nephropathy [37]. The observed effects ofaccurate definition of the renal phenotype was selected.
Identified polymorphic allele frequencies for the AGT the ACE polymorphism in all renal patients and AGT
polymorphism in patients with glomerulonephritis wereand CYP11B2 genes were in accord with frequencies
reported for the general white population [6, 18]. The not biased by differences at the time the renal disease
was determined, as our patients were comparable forACE-D allele frequency was 47%, slightly lower than
the reported range of 50 to 63% for Caucasians [7, 8, renal function and incidence of proteinuria or diabetes
mellitus at the time of renal diagnosis among the differ-11]. This was expected, however, since we used repeated
PCR with intron-specific primers using single-step PCR ent genotype subgroups. No association was found be-
tween AGT, ACE, and CYP11B2 gene polymorphismto avoid overestimation of the DD frequency [29].
There was a genotype balance between control sub- and the age of onset of ESRD, the etiology of renal dis-
ease, the presence of hypertension, and the number ofjects and ESRD patients for the AGT, ACE, or CYP11B2
genotypes. This observation indicates that polymor- antihypertensive drugs used to control blood pressure.
Whenever an association between a gene polymor-phisms in the RAS genes investigated do not account
for the occurrence of renal diseases per se. The most phism and a phenotype is found, two possibilities need
to be considered. First, the observed association mayinteresting finding was the association of the AGT-MM
genotype with the absence of nephropathy and of the be due to the effect of another gene mapping in close
proximity to the one under study. Second, the interactiveAGT-TT genotype with ESRD in patients with diabetes
mellitus (Fig. 1). An association of AGT-T with suscepti- effect of two genes mapping on different chromosomes
and both with a plausible role in causing the phenotypebility to nephropathy in diabetes mellitus type 1 in a
mixed population from Boston [30] or type 2 in aborigi- may lead to an underestimation or an overestimation of
the involvement of the gene under study in determiningnal Canadians [31] has been previously reported. How-
ever, no association was found between the AGT geno- the phenotype. This latter aspect is of particular interest
when the complexity of blood pressure regulation is con-type and nephropathy [32] or microalbuminuria [33] in
two distinct European populations with diabetes mellitus sidered [38]. The context dependency of a gene on the
background of another gene in determining one pheno-type 2, although a recent study in insulin-dependent dia-
betics showed an association of the T allele of AGT with type has been observed in experimental models of hyper-
tension [39] and in humans [40, 41]. When interactionselevated urinary albumin excretion [34]. These contrasting
findings might be due to either ethnic variance or gender between the three genes were analyzed, no significant dif-
ference was found between controls and ESRD patientsdifferences, since the association of the AGT genotype
with diabetic nephropathy has been found in men but for the AGT-ACE, AGT-CYP11B2, or ACE-CYP11B2
genotypes. However, the ACE-DD genotype was foundnot women [30]. To reconcile the contrasting findings
and to confirm our present data, a prospective study with to predict rapid progression to ESRD in AGT-MM ho-
mozygotes (Fig. 2B). Interestingly, an interaction betweena larger number of patients with diabetes mellitus, in
which the onset of renal disease from microalbuminuria AGT and ACE polymorphisms in IgA nephropathy has
already been reported [37], with rapid progression beingto clinical nephropathy to end-stage renal failure will be
monitored in relationship to the AGT genotype, ethnic associated with the AGT-TT allele regardless of the ACE
genotype, while AGT-MM homozygotes had a morebackground and gender are necessary.
The ACE-DD homozygote renal patients showed a rapid progression only when the ACE-DD genotype was
present.more rapid progression to ESRD than ACE-DI or II
subjects (Fig. 2A). The risk associated with the ACE-D These findings indicate that ACE gene polymorphism
is a predictor, albeit weak, of progressive renal functionallele has been found to be more apparent in renal pa-
tients without proteinuria or hypertension [35]. More- loss in patients with renal disease. A relatively stronger
influence of ACE genotype seems apparent in patientsover, the D allele of the ACE gene was associated with
increased urinary albumin excretion in essential hyper- with glomerulonephritis who are homozygous for the
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AGT-MM genotype. The latter has been associated with another study suggested that progression to ESRD may
be more effectively reduced in patients with the DDlower AGT plasma levels as compared with the AGT-TT
genotype [6]. The functional significance of the ACE genotype [24, 47]. In the present population, progression
to ESRD was comparable among men and women withgene I/D polymorphism has been the object of debate.
Plasma ACE activity is higher in DD homozygotes than the DD genotype but was shorter in men with the II or
ID genotype, an observation in line with a previous re-in II homozygotes [7], and pressure response to exoge-
nous angiotensin I is increased in DD homozygotes [42]. port [24], thus suggesting a limited confounding effect
of ACE inhibitor therapy.However, plasma levels of RAS components, that is,
renin, angiotensin II, and aldosterone, were reported The functional relevance of the M235T polymorphism
of the AGT gene and the 344C/T polymorphism ofsimilar in various ACE genotypes [43]. It is possible that
the intrarenal RAS may play a pivotal role with regard the CYP11B2 is a topic under investigation by several
groups. A study in selected hypertensive subjects in twoto the interaction between ACE genotype and progres-
sion of renal diseases independently of plasma renin and distinct American and French populations demonstrated
a higher frequency of the M235T variant of the AGTangiotensin levels [27, 28]. In fact, an exaggerated renal
vasodilator response to angiotensin blockade was ob- gene in hypertensive patients than in controls [6]. Studies
in white Europeans and African Caribbeans on the otherserved in diabetic nephropathy despite low plasma renin
[27]. The role of the ACE gene I/D polymorphism in hand failed to demonstrate a significant linkage with
AGT M235T variants and hypertension [48, 49]. Therenal disease has been recently reviewed by Navis et
al [44]. They identified 16 mostly retrospective studies same is true for the polymorphism in the promoter region
of the CYP11B2 gene at position344 of the SF1 bindingaddressing the issue of ACE I/D polymorphism and pro-
gression of renal function loss. In most studies, the sam- site, where some authors described a weak association
with hypertension [18, 19, 21]. In the present population,ple size was rather limited (10 studies, N  200). In the
presence of the D allele there was an increased risk of there was no association between the CYP11B2 geno-
type and either hypertension in the patients without renallong-term renal function loss, particularly in patients
with both insulin-dependent and non–insulin-dependent failure or rate of progression of renal disease in the
diabetes mellitus. However, studies in patients with IgA ESRD population. Therefore, the 344C/T CYP11B2
nephropathy, autosomal dominant polycystic kidney dis- genotype is probably not a primary candidate for suscep-
ease, and renal conditions of diverse origin yielded mixed tibility or progression of renal disease.
results [44]. These differences in the body of data can In conclusion, susceptibility for ESRD and faster pro-
be explained by several factors. The interpretation of gression to ESRD are linked with the AGT genotype in
data is certainly complicated by methodological limita- diabetic patients. Faster progression to ESRD is associ-
tions inherent to studies of multifactorial diseases by ated with the ACE genotype when the total population
association analyses. Inadequacy in the sample size, ge- with ESRD and with the AGT genotype when patients
netic heterogeneity, and inaccurate definition of the re- with glomerulonephritis are considered. Thus, genes of
nal disease phenotype are additional limiting factors. We the RAS system are candidate genes for the understand-
have attempted to minimize these pitfalls by selecting a ing of the interindividual differences in the development
sufficiently large number of patients with ESRD from and course of ESRD.
one single center and of control subjects. Moreover, our
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